Fintel reports that on May 22, 2025, HC Wainwright & Co. downgraded their outlook for UroGen Pharma (NasdaqGM:URGN) from Buy ...

SAN FRANCISCO, CA / ACCESS Newswire / May 21, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) (“Jaguar” or “the Company”), today ...

Fintel reports that on May 20, 2025, HC Wainwright & Co. initiated coverage of TMC the metals (NasdaqGS:TMC) with a Buy ...

Richtech Robotics reported disappointing quarterly results, with weak sales and poor gross margins. Click here to find out ...

Event: H.C. Wainwright 3rd Annual BioConnect Investor Conference at Nasdaq Location: Nasdaq World Headquarters, New York, NY Fireside Chat: Tuesday, May 20, 12:30 p.m. EST Webcast: ...

Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that it ...

CytomX Therapeutics (CTMX) stock was upgraded to Buy from Neutral at H.C. Wainwright after promising Phase 1 trial results for its colorectal cancer drug. Read more here.

Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today ...

H.C. Wainwright analyst trims BLNK's price forecast to $5, cites product sales weakness. 2025 revenue estimate lowered to $95 ...

In addition, members of XOMA Royalty's business development team will attend the H.C. Wainwright 3 rd Annual BioConnect Investor Conference being held on May 20, 2025, in New York, NY. About XOMA ...

Rosenwald, M.D., Chairman, President and Chief Executive Officer, will participate in the following sessions at the H.C. Wainwright 1 st Annual Royalty Company Virtual Conference, taking place on ...